BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res. 2005;65:2344-2352. [PMID: 15781649 DOI: 10.1158/0008-5472.can-04-3502] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
2 Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z, de Narvajas AA, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK, Kaufmann SH, Billadeau DD. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell Death Dis 2014;5:e1142. [PMID: 24675460 DOI: 10.1038/cddis.2014.102] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
3 Huang X, Yuan F, Liang M, Lo HW, Shinohara ML, Robertson C, Zhong P. M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. PLoS One 2012;7:e41632. [PMID: 22911830 DOI: 10.1371/journal.pone.0041632] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
4 Deng R, Wang X, Liu Y, Yan M, Hanada S, Xu Q, Zhang J, Han Z, Chen W, Zhang P. A new gamboge derivative compound 2 inhibits cancer stem-like cells via suppressing EGFR tyrosine phosphorylation in head and neck squamous cell carcinoma. J Cell Mol Med 2013;17:1422-33. [PMID: 24112466 DOI: 10.1111/jcmm.12129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, Duncan MD, Harmon JW, Ohta T. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clin Exp Med 2017;17:19-31. [PMID: 26449615 DOI: 10.1007/s10238-015-0394-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
6 Samm N, Werner K, Rückert F, Saeger HD, Grützmann R, Pilarsky C. The role of apoptosis in the pathology of pancreatic cancer. Cancers (Basel) 2010;3:1-16. [PMID: 24212603 DOI: 10.3390/cancers3010001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
7 Rückert F, Dawelbait G, Winter C, Hartmann A, Denz A, Ammerpohl O, Schroeder M, Schackert HK, Sipos B, Klöppel G, Kalthoff H, Saeger HD, Pilarsky C, Grützmann R. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One 2010;5:e12243. [PMID: 20808857 DOI: 10.1371/journal.pone.0012243] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kim HY, Kim SL, Park YR, Liu YC, Seo SY, Kim SH, Kim IH, Lee SO, Lee ST, Kim SW. Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells. Intest Res 2015;13:233-41. [PMID: 26130998 DOI: 10.5217/ir.2015.13.3.233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
9 Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb). 2011;3:279-296. [PMID: 21340093 DOI: 10.1039/c0ib00144a] [Cited by in Crossref: 149] [Cited by in F6Publishing: 137] [Article Influence: 13.5] [Reference Citation Analysis]
10 Puskás LG, Mán I, Szebeni G, Tiszlavicz L, Tsai S, James MA. Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. Mol Cancer Ther 2016;15:985-97. [PMID: 26939707 DOI: 10.1158/1535-7163.MCT-15-0717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Ren Y, Chen Z, Chen L, Woods NT, Reuther GW, Cheng JQ, Wang HG, Wu J. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL. J Biol Chem 2007;282:36463-73. [PMID: 17942397 DOI: 10.1074/jbc.M705789200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
12 Zhou L, Qi L, Jiang L, Zhou P, Ma J, Xu X, Li P. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol. AAPS J 2014;16:246-57. [PMID: 24424498 DOI: 10.1208/s12248-013-9558-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
13 Chakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy AM. Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget 2016;7:45959-75. [PMID: 27323855 DOI: 10.18632/oncotarget.10009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
14 Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. PLoS Biol 2007;5:e1. [PMID: 17177603 DOI: 10.1371/journal.pbio.0050001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
15 Jung YH, Heo J, Lee YJ, Kwon TK, Kim YH. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci 2010;86:351-7. [PMID: 20096292 DOI: 10.1016/j.lfs.2010.01.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
16 Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, Sebti SM, Malafa MP. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. J Nutr Biochem 2015;26:797-807. [PMID: 25997867 DOI: 10.1016/j.jnutbio.2015.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
17 Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011;11:431-49. [PMID: 21263219 DOI: 10.4161/cbt.11.5.14671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
18 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med. 2012;60:643-663. [PMID: 22406516 DOI: 10.231/jim.0b013e31824a4d79] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Wang W, Li X, Sun W, Zhang L, Zhang M, Hong B, Lv G. Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression. J Cancer Res Clin Oncol 2012;138:1597-605. [PMID: 22581262 DOI: 10.1007/s00432-012-1235-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
20 Yuan K, Sun Y, Zhou T, McDonald J, Chen Y. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res 2013;19:4750-9. [PMID: 23833311 DOI: 10.1158/1078-0432.CCR-13-0516] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
21 Sun X, Mi L, Liu J, Song L, Chung FL, Gan N. Sulforaphane prevents microcystin-LR-induced oxidative damage and apoptosis in BALB/c mice. Toxicol Appl Pharmacol. 2011;255:9-17. [PMID: 21684301 DOI: 10.1016/j.taap.2011.05.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
22 Kim SS, Cho HJ, Cho JM, Kang JY, Yang HW, Yoo TK. Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells. ScientificWorldJournal 2013;2013:174392. [PMID: 23853530 DOI: 10.1155/2013/174392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J Cell Mol Med 2009;13:1221-7. [PMID: 19382915 DOI: 10.1111/j.1582-4934.2009.00748.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
24 Miyashita T, Miki K, Kamigaki T, Makino I, Tajima H, Nakanuma S, Hayashi H, Takamura H, Fushida S, Ahmed AK, Harmon JW, Ohta T. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B. Oncol Lett 2017;14:5918-26. [PMID: 29113227 DOI: 10.3892/ol.2017.6943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z, de Narvajas AA, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell Death Dis. 2014;5:e1142. [PMID: 24675460 DOI: 10.1038/cddis.2014.341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
26 Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia. 2016;18:765-774. [PMID: 27889645 DOI: 10.1016/j.neo.2016.10.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
27 Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. J Nat Prod 2011;74:1085-92. [PMID: 21486005 DOI: 10.1021/np200029q] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 7.7] [Reference Citation Analysis]
28 Liu J, Xu L, Liu YP, Qu XJ, Zhang Y, Hou KZ, Hu XJ, Jiang YH. Bortezomib enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt pathway. Shijie Huaren Xiaohua Zazhi 2010; 18(18): 1854-1859 [DOI: 10.11569/wcjd.v18.i18.1854] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Vitovski S, Chantry AD, Lawson MA, Croucher PI. Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 2012;7:e35830. [PMID: 22615740 DOI: 10.1371/journal.pone.0035830] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
30 Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 2005;3:22. [PMID: 15943879 DOI: 10.1186/1479-5876-3-22] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 4.5] [Reference Citation Analysis]
31 Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106. [PMID: 21880146 DOI: 10.1186/1476-4598-10-106] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
32 Schizas D, Mastoraki A, Naar L, Spartalis E, Tsilimigras DI, Karachaliou GS, Bagias G, Moris D. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. World J Gastroenterol 2018; 24(41): 4635-4642 [PMID: 30416311 DOI: 10.3748/wjg.v24.i41.4635] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
33 Wang YW, Wang SJ, Zhou YN, Pan SH, Sun B. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 2012;138:785-797. [PMID: 22270965 DOI: 10.1007/s00432-012-1152-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
34 Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis 2018;9:445. [PMID: 29670075 DOI: 10.1038/s41419-018-0478-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
35 Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med 2012;60:643-63. [PMID: 22406516 DOI: 10.2310/JIM.0b013e31824a4d79] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
36 Beckham TH, Lu P, Jones EE, Marrison T, Lewis CS, Cheng JC, Ramshesh VK, Beeson G, Beeson CC, Drake RR, Bielawska A, Bielawski J, Szulc ZM, Ogretmen B, Norris JS, Liu X. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther 2013;344:167-78. [PMID: 23086228 DOI: 10.1124/jpet.112.199216] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
37 Liu J, Qu XJ, Xu L, Zang Y, Qu JL, Hou KZ, Liu YP. Bortezomib synergizes TRAIL-induced apoptosis in gastric cancer cells. Dig Dis Sci. 2010;55:3361-3368. [PMID: 20393880 DOI: 10.1007/s10620-010-1191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
38 Taylor DJ, Parsons CE, Han H, Jayaraman A, Rege K. Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer 2011;11:470. [PMID: 22044796 DOI: 10.1186/1471-2407-11-470] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
39 Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Mol Cancer Ther 2015;14:1570-81. [PMID: 25934708 DOI: 10.1158/1535-7163.MCT-15-0104] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
40 Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer. 2010;9:80. [PMID: 20398369 DOI: 10.1186/1476-4598-9-80] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
41 Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, Byon CH, McDonald JM. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 2006;169:1833-42. [PMID: 17071604 DOI: 10.2353/ajpath.2006.060234] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
42 Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira P, Urabayashi MS, Martens AA, Neves JH, Machado-Santelli GM. The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res 2014;33:37. [PMID: 24775603 DOI: 10.1186/1756-9966-33-37] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 9.6] [Reference Citation Analysis]
43 Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009;69:5592-600. [PMID: 19531648 DOI: 10.1158/0008-5472.CAN-09-0838] [Cited by in Crossref: 78] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
44 Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL. Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol 2015;388:623-34. [PMID: 25743573 DOI: 10.1007/s00210-015-1107-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
45 Rikiishi H. Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors. Cancers (Basel) 2010;2:2026-43. [PMID: 24281216 DOI: 10.3390/cancers2042026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
46 Chang Z, Zhang Y, Liu J, Guan C, Gu X, Yang Z, Ye Q, Ding L, Liu R. GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway. J Oncol 2019;2019:9474273. [PMID: 31093285 DOI: 10.1155/2019/9474273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B, Ouaissi A. Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011;2011:315939. [PMID: 20981265 DOI: 10.1155/2011/315939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
48 Su S, Shi X, Xu W, Li Y, Chen X, Jia S, Sun S. Antifungal Activity and Potential Mechanism of Panobinostat in Combination With Fluconazole Against Candida albicans. Front Microbiol 2020;11:1584. [PMID: 32765454 DOI: 10.3389/fmicb.2020.01584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008;283:25003-13. [PMID: 18599488 DOI: 10.1074/jbc.M802511200] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
50 Yuan K, Yong S, Xu F, Zhou T, McDonald JM, Chen Y. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer. Oncotarget 2015;6:25308-19. [PMID: 26320171 DOI: 10.18632/oncotarget.4490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
51 Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, Bansal S. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 2012;287:32875-80. [PMID: 22898820 DOI: 10.1074/jbc.C112.366559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
52 Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Mol Cancer Ther 2011;10:2363-72. [PMID: 21971120 DOI: 10.1158/1535-7163.MCT-11-0424] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
53 Fulda S. Targeting apoptosis signaling in pancreatic cancer. Cancers (Basel). 2011;3:241-251. [PMID: 24212616 DOI: 10.3390/cancers3010241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
54 Nakajima T, Wang B, Ono T, Uehara Y, Nakamura S, Ichinohe K, Braga-Tanaka I 3rd, Tanaka S, Tanaka K, Nenoi M. Differences in sustained alterations in protein expression between livers of mice exposed to high-dose-rate and low-dose-rate radiation. J Radiat Res 2017;58:421-9. [PMID: 28201773 DOI: 10.1093/jrr/rrw133] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sellers RP, Alexander LD, Johnson VA, Lin CC, Savage J, Corral R, Moss J, Slugocki TS, Singh EK, Davis MR, Ravula S, Spicer JE, Oelrich JL, Thornquist A, Pan CM, McAlpine SR. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives. Bioorg Med Chem 2010;18:6822-56. [PMID: 20708938 DOI: 10.1016/j.bmc.2010.07.042] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.3] [Reference Citation Analysis]